← Leaderboards
Tracey McLaughlin
Stanford University
$5,362,409
Attributed
$7,329,245
Total exposure
12
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $849.7K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,329,245 · 12
By mechanism
R01$5,073,403 · 3
M01$1,195,995 · 7
K23$626,922 · 1
R21$432,925 · 1
Top collaborators
- Michael P Snyder6 shared
Most similar at Stanford University
Same institution · by research overlap
- Jinnie J. Rhee$877,425
- Jonathan Nizar$830,579
- Gerald M. Reaven$10,248,115
- David E Salt$1,630,701
- Eric Sibley$7,139,073
Others in their field
Top investigators on “Obesity”
- Chanza Baytop · Westat, Inc.$271,217,917
- Judith S. Currier · University Of California Los Angeles$139,907,800
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$137,892,773
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$108,827,660
- Peter Gordon Gillespie · Oregon Health And Science University$104,808,120
- Joseph E Robertson · Oregon Health & Science University$93,739,249
Research focus
ObesityInsulinAdipose TissueFatty Acid Glycerol EstersInsulin ResistanceLinkSubcutaneousResponseCardiovascular DiseasesNon-Insulin-Dependent Diabetes MellitusImpairmentBody Weight DecreasedCellsHuman SubjectOverweightMediatingBiopsyBiologicalCharacteristicsWeightMorbidity - Disease RateLiverPrevalenceGene Proteins
Grant awards (23)
Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention$714,440
R01 · FY2025 · DK · contact PI
Obesity and COVID-19: Role of Adipose Tissue$196,750
R21 · FY2022 · AI · contact PI
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance$613,555
R01 · FY2021 · DK · contact PI
Obesity and COVID-19: Role of Adipose Tissue$236,175
R21 · FY2021 · AI · contact PI
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance$628,341
R01 · FY2020 · DK · contact PI
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance$644,262
R01 · FY2019 · DK · contact PI
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance$659,369
R01 · FY2018 · DK · contact PI
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance$673,705
R01 · FY2017 · DK · contact PI
Heterogeneity of Fat Depots: Biological Differences Related to Insulin Resistance$376,154
R01 · FY2011 · DK · contact PI
Heterogeneity of Fat Depots: Biological Differences Related to Insulin Resistance$379,973
R01 · FY2010 · DK · contact PI
Heterogeneity of Fat Depots: Biological Differences Related to Insulin Resistance$383,604
R01 · FY2009 · DK · contact PI
WHAT ARE THE UNIQUE BENEFITS OF PIOGLITAZONE COMPARED TO WEIGHT LOSS$57,795
M01 · FY2008 · RR · contact PI
INSULIN RESISTANCE: IT'S ROLE IN WEIGHT LOSS AND CARDIOVASCULAR RISK$5,575
M01 · FY2008 · RR · contact PI
WHAT ARE THE UNIQUE BENEFITS OF PIOGLITAZONE COMPARED TO WEIGHT LOSS$193,683
M01 · FY2007 · RR · contact PI
INSULIN RESISTANCE: IT'S ROLE IN WEIGHT LOSS AND CARDIOVASCULAR RISK$177,884
M01 · FY2007 · RR · contact PI
INSULIN RESISTANCE: IT'S ROLE IN WEIGHT LOSS AND CARDIOVASCULAR RISK$227,728
M01 · FY2006 · RR · contact PI
ROLE OF ADIPOCYTES IN INSULIN RESISTANCE AND CARDIOVASULAR DISEASE$16,456
M01 · FY2006 · RR · contact PI
INSULIN RESISTANCE: IT'S ROLE IN WEIGHT LOSS AND CARDIOVASCULAR RISK$516,874
M01 · FY2005 · RR
Mentored Patient-Oriented Research Career Development Aw$125,761
K23 · FY2004 · RR
Mentored Patient-Oriented Research Career Development Aw$126,247
K23 · FY2003 · RR
Mentored Patient-Oriented Research Career Development Aw$126,657
K23 · FY2002 · RR
Mentored Patient-Oriented Research Career Development Aw$127,003
K23 · FY2001 · RR
Mentored Patient-Oriented Research Career Development Aw$121,254
K23 · FY2000 · RR